Transgenic mice expressing mutant human amyloid precursor protein (APP) develop an age-dependent amyloid pathology and memory deficits, but no overt neuronal loss. Here, in mice overexpressing wild-type human APP (hAPP wt ) we found an early memory impairment, particularly in the water maze and to a lesser extent in the object recognition task, but β-amyloid peptide (Aβ 42 ) was barely detectable in the hippocampus. In these mice, hAPP processing was basically non-amyloidogenic, with high levels of APP carboxy-terminal fragments, C83 and APP intracellular domain. A tau pathology with an early increase in the levels of phosphorylated tau in the hippocampus, a likely consequence of enhanced ERK1/2 activation, was also observed. Furthermore, these mice presented a loss of synapse-associated proteins: PSD95, AMPA and NMDA receptor subunits and phosphorylated CaMKII. Importantly, signs of neurodegeneration were found in the hippocampal CA1 subfield and in the entorhinal cortex that were associated to a marked loss of MAP2 immunoreactivity. Conversely, in mice expressing mutant hAPP, high levels of Aβ 42 were found in the hippocampus, but no signs of neurodegeneration were apparent. The results support the notion of Aβ-independent pathogenic pathways in Alzheimer's disease.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder usually characterized by two histopathological hallmarks, amyloid plaques, mainly composed of the β-amyloid (Aβ) peptide, and intracellular neurofibrillary tangles, comprising aggregates of hyperphosphorylated protein tau. Other neuropathological hallmarks, early synaptic dysfunction and selective neuronal loss, are nowadays considered the best correlate of cognitive decline in AD (Selkoe, 2002; Walsh and Selkoe, 2004) . According to the β-amyloid hypothesis, Aβ is the initiating cause of AD. This peptide is proteolytically generated from the larger amyloid precursor protein (APP) that is cleaved by β-secretase releasing a soluble fragment (sAPPβ) and a carboxy-terminal fragment (CTF), C99, within the membrane. The γ-secretase complex cleaves the latter fragment releasing the Aβ peptide and the APP intracellular domain (AICD). APP can be also processed by a non-amyloidogenic pathway that includes the proteolysis of APP by α-secretase, within the Aβ region, to generate a secreted soluble protein (sAPPα) and a CTF named C83. Further cleavage of C83 by γ-secretase generates p3 peptide and the AICD fragment. Different reports indicate that not only Aβ is neurotoxic, but also the CTFs may alter neuronal survival. In particular, the AICD, generated from C83 or C99 fragments, has been identified in transgenic mouse brains overexpressing human APP (hAPP) as well as in AD brain tissue and may have a critical pathophysiological role (Passer et al., 2000; Shin et al., 2007) .
Some studies have provided evidence for an intrinsic central role of APP in the pathogenesis of AD and have suggested that this disease may be a consequence of a disruption of APP normal function (Neve et al., 2000) . APP is not only important for CNS maturation but plays also a role in cell contact and adhesion, in neuronal morphogenesis, in the maintenance of synaptic transmission and plasticity and may even induce a neurotrophic effect (Alpár et al., 2006; Priller et al., 2006; Oh et al., 2008) . Accordingly, APP knockout mice develop behavioral and cognitive impairment (Dawson et al., 1999; Phinney et al., 1999) . Despite the physiological role of APP, several studies have shown that APP overexpression may lead to an increased generation of toxic derivatives, Aβ peptide and/or CTFs. Moreover, APP overproduction, either as a result of genomic locus duplication or altered regulatory sequences in the APP promoter region, leads to early-onset AD in humans (Cabrejo et al., 2006; Rovelet-Lecrux et al., 2006) .
Several transgenic mouse models for AD carrying mutations of hAPP, presenilins, tau or different combinations have been generated for the production of an Alzheimer-type neuropathology (Van Dam and De Deyn, 2006) . However, a complete mouse model recapitulating all aspects of the disease has not yet been produced. In transgenic Neurobiology of Disease 33 (2009) 369-378 
